Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Advances in nmCRPC

Jeanny Aragon-Ching • 3 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer Apalutamide Darolutamide Enzalutamide

Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, VA, speaks at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, and explains what is changing the in the treatment landscape of nmCRPC and what we can expect in the future.

More from Jeanny Aragon-Ching

1:13
GU cancer: treating elderly patients
Jeanny Aragon-Ching • 2 Jun 2019
2:03
Current approaches to treating urothelial cancer
Jeanny Aragon-Ching • 2 Jun 2019
2:02
Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma
Jeanny Aragon-Ching • 8 Mar 2019
2:06
PRIMETEST: evaluating retroperitoneal lymph node dissection
Jeanny Aragon-Ching • 15 Feb 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals